Effect of upadacitinib on extraintestinal manifestations in patients with moderately to severely active Crohn's disease

被引：0

作者：

Wright, Emily K. ^{[1
,2
]}

Colombel, Jean-Frederic ^{[3
]}

Hudesman, David ^{[4
]}

Cao, Qian ^{[7
]}

Ghosh, Subrata ^{[8
]}

Reinisch, Walter ^{[9
]}

Lacerda, Ana ^{[5
]}

Dubcenco, Elena ^{[5
]}

Doshi, Chirag ^{[5
]}

Anyanwu, Samuel ^{[5
]}

Feng, Tian ^{[5
]}

Rubin, David ^{[6
]}

机构：

[1] St Vincents Hosp, Melbourne, Vic, Australia

[2] Univ Melbourne, Melbourne, Vic, Australia

[3] Icahn Sch Med Mt Sinai, Div Gastroenterol, New York, NY USA

[4] NYU Langone Hlth, Div Gastroenterol, Ctr Inflammatory Bowel Dis, New York, NY USA

[5] AbbVie Inc, N Chicago, IL USA

[6] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA

[7] Zhejiang Univ, Sir Run Shaw Hosp, Ctr Inflammatory Bowel Dis, Coll Med,Dept Gastroenterol, Hangzhou, Peoples R China

[8] Univ Coll Cork, Coll Med & Hlth, Cork, Ireland

[9] Med Univ Vienna, Clin Dept Gastroenterol & Hepatol, Vienna, Austria

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：159 / 160

页数：2

共 50 条

[21] Extraintestinal Manifestations Are Common in Obese Patients with Crohn's Disease
Singla, Manish B.
Eickhoff, Christa
Betteridge, John
INFLAMMATORY BOWEL DISEASES, 2017, 23 (09) : 1637 - 1642
[22] Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease: U-ENDURE Phase 3 Results
Panes, Julian
Loftus, Edward, Jr.
Lacerda, Ana
Peyrin-Biroulet, Laurent
D'Haens, Geert
Panaccione, Remo
Reinisch, Walter
Louis, Edouard
Chen, Minhu
Nakase, Hiroshi
Begun, Jakob
Boland, Brigid
Liu, Jianzhong
Dubcenco, Elena
Mohamed, Mohamed-Eslam
Feng, Tian
Colombel, Jean-Frederic
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S10 - S10
[23] UPADACITINIB EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE - ANALYSIS OF CELEST STUDY
Mohamed, Mohamed-Eslam F.
Kluender, Ben
Lacerda, Ana P.
Othman, Ahmed A.
GASTROENTEROLOGY, 2018, 154 (06) : S386 - S386
[24] EFFECT OF UPADACITINIB ON LIPID PROFILES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: POOLED ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE OR ULCERATIVE COLITIS
Dubinsky, Marla C.
Ha, Christina
Armuzzi, Alessandro
Irving, Peter M.
Fumery, Mathurin
Anyanwu, Samuel
Lacerda, Ana P.
Wang, Tao
Suravaram, Smitha
Kligys, Kristina
Shah, Saajan
Duncan, Benjamin
Rubin, David T.
GASTROENTEROLOGY, 2024, 166 (05) : S813 - S813
[25] Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn's disease
Reinisch, W.
Colombel, J. F.
Ma, C.
Long, M.
Irving, P. M.
O'Brien, D.
Kligys, K.
Song, A.
Zhang, Y.
D'Haens, G.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1378 - I1379
[26] Efficacy and safety of risankizumab therapy in Chinese patients with moderately to severely active crohn's disease
Gao, X.
Cao, Q.
Ran, Z. H.
Chen, Y. X.
Chen, Y.
Wen, Z. H.
Liu, D. L.
Ding, J.
Zhong, J.
Liu, F.
Sha, W. H.
An, P.
Wang, B. M.
Hu, L. X.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1298 - i1299
[27] Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's disease: results from the U-ENDURE long-term extension
Mitrev, Nikola
D'Haens, Geert
Louis, Edouard
Loftus, Edward, Jr.
Regueiro, Miguel
Jairath, Vipul
Magro, Fernando
Nakase, Hiroshi
Dubcenco, Elena
Lacerda, Ana
Feng, Tian
Duncan, Benjamin
Wang, Tao
Ford, Sharanya
Anyanwu, Samuel
Blumenstein, Irina
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 161 - 162
[28] Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's Disease: results from the U-ENDURE long-term extension
D'Haens, G.
Louis, E.
Loftus, E. V.
Regueiro, M.
Jairath, V.
Magro, F.
Nakase, H.
Dubcenco, E.
Lacerda, A. P.
Feng, T.
Duncan, B.
Wang, T.
Ford, S.
Anyanwu, S. I.
Blumenstein, I.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I17 - I18
[29] MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
Reguiro, Miguel D.
Fischer, Monika
Rubin, David T.
Shan, Mingyang
Deckard, Deanilee
Pollack, Paul
Hunter, Theresa
Chan, Lai Shan
Hindryckx, Pieter
GASTROENTEROLOGY, 2021, 160 (06) : S354 - S355
[30] Sustained Remission with Adalimumab Therapy in Japanese Patients with Moderately to Severely Active Crohn's Disease
Hibi, Toshifumi
Watanabe, Mamoru
Kumar, Ashish
Camez, Anne
Lomax, Kathleen
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S463 - S463

← 1 2 3 4 5 →